We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Milford, Massachusetts-based Waters Corporation (WAT - Free Report) is a prominent medical instrument supplying firm, conducting trade in the healthcare sector. The company is renowned analytical instrument producer but also builds up and supplies software-based products to its customers.
WAT’s global pharmaceuticals business, its largest single market and major revenue driver, is the company’s major profit churner fuelling its growth. Waters Corp.’s solid market presence in both high-performance liquid chromatography market and mass spectrometry markets, strength in regulated testing, non-discretionary product demand are its staple growth drivers.
Also, the company’s robust product portfolio supplements its strength. Thriving life sciences and analytical instrument markets, accelerated drug approvals by the FDA and favorable funding environment bode well for the company’s future growth.
Despite the positives, Waters Corp.’s debt levels and the consequent interest expenses remain a burden, given its recent acquisitions. Also, rising R&D expenses and volatility in client spending add to the company’s woes.
In the last quarter, Waters Corp. had posted an earnings beat of 1.7%. The company boasts a solid earnings track record, having beaten estimates all through in the trailing four quarters. The average earnings surprise over the last four quarters is a positive 4.3%.
We have highlighted some of the key details from the just-released announcement below:
Earnings: WAT beat on earnings. Adjusted earnings per share came in at $2.51, higher than the Zacks Consensus Estimate of $2.44.
Revenue: Revenues came in at $687 million, ahead of the Zacks Consensus Estimate of $671 million and grew 9% over the prior-year quarter’s tally.
Key Stats: Waters witnessed robust sales growth in Europe, United States and Asia. Also, strong, broad-based market traction in the bio/pharmaceutical end markets and impressive performance from service and chemistry consumables drove the impressive results.
Stock Price: WAT shares were inactive following the release. It would be interesting to see how the market reacts to the results during the trading session today.
Check back later for our full write up on this WAT earnings report!
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Image: Bigstock
Waters Corp. (WAT) Q4 Earnings, Revenues Beat Estimates
Milford, Massachusetts-based Waters Corporation (WAT - Free Report) is a prominent medical instrument supplying firm, conducting trade in the healthcare sector. The company is renowned analytical instrument producer but also builds up and supplies software-based products to its customers.
WAT’s global pharmaceuticals business, its largest single market and major revenue driver, is the company’s major profit churner fuelling its growth. Waters Corp.’s solid market presence in both high-performance liquid chromatography market and mass spectrometry markets, strength in regulated testing, non-discretionary product demand are its staple growth drivers.
Also, the company’s robust product portfolio supplements its strength. Thriving life sciences and analytical instrument markets, accelerated drug approvals by the FDA and favorable funding environment bode well for the company’s future growth.
Despite the positives, Waters Corp.’s debt levels and the consequent interest expenses remain a burden, given its recent acquisitions. Also, rising R&D expenses and volatility in client spending add to the company’s woes.
In the last quarter, Waters Corp. had posted an earnings beat of 1.7%. The company boasts a solid earnings track record, having beaten estimates all through in the trailing four quarters. The average earnings surprise over the last four quarters is a positive 4.3%.
Waters Corporation Price and EPS Surprise
Waters Corporation Price and EPS Surprise | Waters Corporation Quote
Currently, WAT has a Zacks Rank #3 (Hold) but that could change following its fourth-quarter 2017 earnings report which has just released. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
We have highlighted some of the key details from the just-released announcement below:
Earnings: WAT beat on earnings. Adjusted earnings per share came in at $2.51, higher than the Zacks Consensus Estimate of $2.44.
Revenue: Revenues came in at $687 million, ahead of the Zacks Consensus Estimate of $671 million and grew 9% over the prior-year quarter’s tally.
Key Stats: Waters witnessed robust sales growth in Europe, United States and Asia. Also, strong, broad-based market traction in the bio/pharmaceutical end markets and impressive performance from service and chemistry consumables drove the impressive results.
Stock Price: WAT shares were inactive following the release. It would be interesting to see how the market reacts to the results during the trading session today.
Check back later for our full write up on this WAT earnings report!
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Click for details >>